Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.
暂无分享,去创建一个
S Michiels | C Desmedt | C Sotiriou | S Loi | S Loibl | C Denkert | C. Sotiriou | S. Loi | C. Desmedt | M. Piccart | C. Denkert | V. Kataja | S. Loibl | S. Michiels | R. Salgado | H. Joensuu | N. Sirtaine | P. Kellokumpu-Lehtinen | D. Fumagalli | M. Smyth | P. Bono | M J Piccart | D Fumagalli | V Kataja | V. Jose | M. Smyth | H Joensuu | R Salgado | N Sirtaine | V Jose | P-L Kellokumpu-Lehtinen | P Bono | M J Smyth | C. Denkert | N. Sirtaine
[1] J. Baselga,et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. , 2012, The New England journal of medicine.
[2] R. Gray,et al. Abstract S1-07: Prognostic value of tumor-infiltrating lymphocytes (TILs) in two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199 , 2013 .
[3] S. Loi,et al. Anti–ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti–PD-1 or anti-CD137 mAb therapy , 2011, Proceedings of the National Academy of Sciences.
[4] Eric C. Sorenson,et al. Imatinib Potentiates Anti-tumor T Cell Responses in Gastrointestinal Stromal Tumor through the Inhibition of Ido Nih Public Access Author Manuscript , 2022 .
[5] C. Sotiriou,et al. Abstract S1-05: Tumor infiltrating lymphocytes (TILs) indicate trastuzumab benefit in early-stage HER2-positive breast cancer (HER2+ BC) , 2013 .
[6] Stefan Michiels,et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] L. Zitvogel,et al. Anticancer effects of imatinib via immunostimulation , 2011, Nature Medicine.
[8] C. Perou,et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] T. Graeber,et al. Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. , 2013, The Journal of clinical investigation.
[10] Laurence Zitvogel,et al. Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy , 2007, Nature Medicine.
[11] R. Schreiber,et al. Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion , 2011, Science.
[12] R. Gelber,et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial , 2012, The Lancet.
[13] P. Beckhove,et al. The shaping of a polyvalent and highly individual T-cell repertoire in the bone marrow of breast cancer patients. , 2006, Cancer research.
[14] Soonmyung Paik,et al. Use of archived specimens in evaluation of prognostic and predictive biomarkers. , 2009, Journal of the National Cancer Institute.
[15] Hua Guo,et al. Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways , 2011, Nature Medicine.
[16] Carsten Denkert,et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Dennie T. Frederick,et al. Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma , 2012, Clinical Cancer Research.
[18] B. Chauffert,et al. Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy , 2010, Breast Cancer Research and Treatment.
[19] F. Penault-Llorca,et al. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? , 2006, British Journal of Cancer.
[20] Kavya Rakhra,et al. CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. , 2010, Cancer cell.
[21] S. Loi,et al. Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors. , 2011, Cancer research.
[22] Gabriela Alexe,et al. High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates. , 2007, Cancer research.
[23] S. Manolagas. Steroids and osteoporosis: the quest for mechanisms. , 2013, The Journal of clinical investigation.
[24] J. Blay,et al. Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients. , 2009, Cancer research.
[25] C. Leclerc,et al. The T-cell receptor repertoire of tumor-infiltrating regulatory T lymphocytes is skewed toward public sequences. , 2012, Cancer research.
[26] P. Fumoleau,et al. T-bet expression in intratumoral lymphoid structures after neoadjuvant trastuzumab plus docetaxel for HER2-overexpressing breast carcinoma predicts survival , 2011, British Journal of Cancer.
[27] L. Presta,et al. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets , 2000, Nature Medicine.
[28] C. Lawton,et al. Tumor-Infiltrating CD8+ Lymphocytes Predict Clinical Outcome in Breast Cancer , 2012 .
[29] Stefan Michiels,et al. Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] J. Thigpen,et al. Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer , 2012 .
[31] Ming Tan,et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. , 2004, Cancer cell.
[32] K. Shen,et al. Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer , 2008 .
[33] S. Ménard,et al. Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2 , 2004, Clinical Cancer Research.
[34] Jorma Isola,et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] Gianluca Bontempi,et al. Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes , 2008, Clinical Cancer Research.
[36] P. Grambsch,et al. Proportional hazards tests and diagnostics based on weighted residuals , 1994 .
[37] J. Fricker. San Antonio Breast Cancer Symposium. , 2009, The Lancet. Oncology.
[38] V. Kosma,et al. Lymphocyte infiltrates as a prognostic variable in female breast cancer. , 1992, European journal of cancer.
[39] M. Greene,et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. , 2010, Cancer cell.